Omeros Corporation (OMER)
OMERNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$17.30
-0.2500 (-1.42%) today
At the close, Nov 10, 4:00 PM ET. After hours $17.36 +0.35%
- Market cap
- $1.25bn
- P/E
- 6.3
- EPS, last 4 quarters
- $2.73
- Dividend yield
- –
- Day range
- $17.06 to $17.83
- 52-week range
- $6.24 to $21.24
- Average volume
- 1.26m
- Previous close
- $17.55
Analysts
3 coveringBuy2 buy, 1 hold, 0 sell
Targets a year out average $27.50, +59.0% from here
Earnings
next estimate $-0.0500Next report Nov 12, 2026
Sep 2025
+67.2%
Dec 2025
+670.9%
Mar 2026
+40.0%
Jun 2026
+107.4%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | $9.89m | $28.53m |
| Gross profit | – | – | $9.31m | $27.73m |
| Operating income | -$26.39m | -$29.08m | -$17.42m | $74.0k |
| Net income | -$30.92m | $86.45m | $56.06m | $13.23m |
News
8 latest- Stock Indexes Finish Sharply Lower as Tech Stocks PlungeBarchart · Oct 19, 2026
- Stock Indexes Mostly Lower as Chipmaker Weakness PersistsBarchart · Oct 16, 2026
- Stocks are Mixed on Rotation Out of Chipmakers and AI StocksBarchart · Oct 16, 2026
- Omeros Receives Second CHMP Rejection For Narsoplimab In Europe; Stock Down RTTNews · Oct 16, 2026
- Omeros: CHMP Issues Negative Opinion On Marketing Authorization Application For Narsoplimab RTTNews · Oct 16, 2026
- Add Up The Pieces: IHE Could Be Worth $116BNK Invest · Sep 28, 2026
- Biotech Stocks At 52-Week Highs - OMER +13%, TKNO +5%, BLFS, SDGR, INFU RTTNews · Sep 23, 2026
- What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?Zacks · Aug 28, 2026
The company
Omeros is an innovative biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for both large-market and orphan indications, with a focus on the treatment of complement-mediated diseases, cancers, and addictive or compulsive disorders. Omeros' lead complement inhibitor YARTEMLEA® (narsoplimab-wuug), which targets the lectin pathway's effector enzyme MASP-2, is FDA-approved and commercially available in the U.S. for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adult and pediatric patients two years of age and older. OMS1029, Omeros' long-acting MASP-2 inhibitor, has successfully completed Phase 1 clinical trials.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- omeros.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.